Comparative analysis of oral delivery systems for live rotavirus vaccines

被引:11
作者
Duncan, JD
Wang, PX
Harrington, CM
Schafer, DP
Matsuoka, Y
Mestecky, JF
Compans, RW
Novak, MJ
机构
[1] SECRETECH INC, BIRMINGHAM, AL 35205 USA
[2] EMORY UNIV, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA
[3] UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA
基金
美国国家卫生研究院;
关键词
rotavirus; oral delivery systems; tableting; microspheres; non-pareil seeds; oral vaccination;
D O I
10.1016/0168-3659(96)01331-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this paper a comparison of delivery systems for a live rotavirus vaccine is presented. The loss of infectivity was estimated during incorporation into the delivery systems, and during the subsequent processing steps in the preparation of poly(DL-lactide-co-glycolide) microspheres, alginate microcapsules, spray-coated non-pareil seeds, granules, and tablets. Incorporation of live rotavirus into DL-PLG microspheres or alginate microcapsules, as well as the application to the surface of non-pareil seeds resulted in a complete or significant loss of rotavirus infectivity. In contrast, stabilization of the rotavirus vaccine with an excipient blend of cellulose, starch, sucrose and gelatin (30:30:30:10), followed by incorporation into granules or tablets, produced outstanding results with only minimal losses of infectivity. Of these two delivery systems tablets produced better results. However, the dosage form must be modified into a formulation suitable for immunizing infants.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 21 条
[1]   DEVELOPMENT OF CANDIDATE ROTAVIRUS VACCINES [J].
BISHOP, RF .
VACCINE, 1993, 11 (02) :247-254
[2]  
BISHOP RF, 1986, DEV VACCINES DRUGS D, P158
[3]  
COWSAR DR, 1985, METHOD ENZYMOL, V112, P101
[4]   PERSPECTIVE ON THE DEVELOPMENT AND DEPLOYMENT OF ROTAVIRUS VACCINES [J].
EDELMAN, R .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (08) :704-710
[5]   ROTAVIRUS STABILITY AND INACTIVATION [J].
ESTES, MK ;
GRAHAM, DY ;
SMITH, EM ;
GERBA, CP .
JOURNAL OF GENERAL VIROLOGY, 1979, 43 (MAY) :403-409
[6]   PROTEOLYTIC ENHANCEMENT OF ROTAVIRUS INFECTIVITY - MOLECULAR MECHANISMS [J].
ESTES, MK ;
GRAHAM, DY ;
MASON, BB .
JOURNAL OF VIROLOGY, 1981, 39 (03) :879-888
[7]   REACTIONS TO AND ANTIGENICITY OF 2 HUMAN-RHESUS ROTAVIRUS REASSORTANT VACCINE CANDIDATES OF SEROTYPE-1 AND SEROTYPE-2 IN VENEZUELAN INFANTS [J].
FLORES, J ;
PEREZSCHAEL, I ;
BLANCO, M ;
VILAR, M ;
GARCIA, D ;
PEREZ, M ;
DAOUD, N ;
MIDTHUN, K ;
KAPIKIAN, AZ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (03) :512-518
[8]   HUMAN-RHESUS REASSORTANT ROTAVIRUS VACCINES - SAFETY AND IMMUNOGENICITY IN ADULTS, INFANTS, AND CHILDREN [J].
HALSEY, NA ;
ANDERSON, EL ;
SEARS, SD ;
STEINHOFF, M ;
WILSON, M ;
BELSHE, RB ;
MIDTHUN, K ;
KAPIKIAN, AZ ;
CHANOCK, RM ;
SAMORODIN, R ;
BURNS, B ;
CLEMENTS, ML .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (06) :1261-1267
[9]   AN EPIDEMIC OF ROTAVIRUS-ASSOCIATED GASTROENTERITIS IN A NURSING-HOME FOR THE ELDERLY [J].
HALVORSRUD, J ;
ORSTAVIK, I .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1980, 12 (03) :161-164
[10]   ROTAVIRUS AS A CAUSE OF DIARRHEAL MORBIDITY AND MORTALITY IN THE UNITED-STATES [J].
HO, MS ;
GLASS, RI ;
PINSKY, PF ;
ANDERSON, LJ .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (05) :1112-1116